Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Gross Margin (2016 - 2017)

Lisata Therapeutics filings provide 8 years of Gross Margin readings, the most recent being 1.51% for Q1 2017.

  • For the quarter ending Q1 2017, Gross Margin fell 1835.0% year-over-year to 1.51%, compared with a TTM value of 7.75% through Mar 2017, up 2731.0%, and an annual FY2016 reading of 11.76%, up 140.0% over the prior year.
  • Gross Margin hit 1.51% in Q1 2017 for Lisata Therapeutics, down from 9.15% in the prior quarter.
  • The five-year high for Gross Margin was 19718.99% in Q3 2013, with the low at 97334.9% in Q3 2014.
  • Median Gross Margin over the past 5 years was 7.58% (2016), compared with a mean of 22823.91%.
  • The sharpest move saw Gross Margin crashed -11705389bps in 2014, then soared 9735323bps in 2015.
  • Year by year, Gross Margin stood at 18000.22% in 2013, then plummeted by -538bps to 78810.29% in 2014, then decreased by -4bps to 81682.29% in 2015, then skyrocketed by 100bps to 9.15% in 2016, then crashed by -116bps to 1.51% in 2017.
  • According to Business Quant data, Gross Margin over the past three periods came in at 1.51%, 9.15%, and 7.58% for Q1 2017, Q4 2016, and Q3 2016 respectively.